{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T08:45:37Z","timestamp":1764665137200,"version":"3.46.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T00:00:00Z","timestamp":1757203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is a demand for population level research on the potential genetic-basis of mesothelioma (e.g. BRCA1-associated protein-1 [BAP1]) independent of other risk factors, such as amphibole asbestos exposure. By surrogate, another primary cancer history can be used to explore this issue, including in the USA, where the incidence rates (IRs) in men, but not women, are temporally aligned with historical asbestos consumption.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We computed age-adjusted IRs of mesothelioma in females and males stratified by other primary cancer history using publicly available U.S. cancer data from 1975 to 2021. To facilitate comparison with other cancers associated with BAP1, we calculated age-adjusted IRs for female breast cancer and melanoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Similar to breast cancer and melanoma, ~\u200925% of females with mesothelioma had a history of at least one other primary cancer. While IRs of mesothelioma in males without a history of other primary cancers were temporally aligned with historical asbestos consumption trends in the USA, IRs of mesothelioma among males with other primary cancer histories showed no relationship with asbestos consumption trends.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings suggest that a genetic predisposition for malignancy contributes to U.S. mesothelioma rates and is a distinct risk factor independent of asbestos exposure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/pubmed\/fdaf110","type":"journal-article","created":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T17:30:47Z","timestamp":1757266247000},"page":"e540-e545","source":"Crossref","is-referenced-by-count":0,"title":["Potential influence of cancer history on mesothelioma incidence: an ecologic analysis in the U.S. population"],"prefix":"10.1093","volume":"47","author":[{"given":"Callan F","family":"Krevanko","sequence":"first","affiliation":[{"name":"Benchmark Risk Group , 720 SE 160th Ave Suite 103, PMB 264 Vancouver, WA 98684 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley M","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Benchmark Risk Group , 121 West Wacker Dr., Suite 2800 Chicago, IL 60601 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison M","family":"Gauthier","sequence":"additional","affiliation":[{"name":"Benchmark Risk Group , 1111 Broadway, Suite 300 Oakland, CA 94607 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moin S","family":"Vahora","sequence":"additional","affiliation":[{"name":"Benchmark Risk Group , 121 West Wacker Dr., Suite 2800 Chicago, IL 60601 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5256-6143","authenticated-orcid":false,"given":"Ryan C","family":"Lewis","sequence":"additional","affiliation":[{"name":"Benchmark Risk Group , 1111 Broadway, Suite 300 Oakland, CA 94607 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer S","family":"Pierce","sequence":"additional","affiliation":[{"name":"Benchmark Risk Group , 121 West Wacker Dr., Suite 2800 Chicago, IL 60601 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,9,7]]},"reference":[{"volume-title":"SEER*Explorer","author":"NCI SEER Program","key":"2025120203430494600_ref1"},{"key":"2025120203430494600_ref2","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/10408444.2022.2082919","article-title":"Projection of future numbers of mesothelioma cases in the US and the increasing prevalence of background cases: an update based on SEER data for 1975 through 2018","volume":"52","author":"Price","year":"2022","journal-title":"Crit Rev Toxicol"},{"key":"2025120203430494600_ref3","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1001\/jamaoncol.2017.3605","article-title":"Prevalence of prior cancer among persons newly diagnosed with cancer: an initial report from the surveillance, epidemiology, and end results program","volume":"4","author":"Murphy","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025120203430494600_ref4","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1001\/jamaoncol.2023.1723","article-title":"An updated report on the prevalence of prior cancer among persons newly diagnosed with cancer in the surveillance, epidemiology, and end results program","volume":"9","author":"Murphy","year":"2023","journal-title":"JAMA Oncol"},{"key":"2025120203430494600_ref5","doi-asserted-by":"publisher","first-page":"30649","DOI":"10.18632\/oncotarget.25769","article-title":"Clinical genetic testing outcome with multi-gene panel in Asian patients with multiple primary cancers","volume":"9","author":"Chan","year":"2018","journal-title":"Oncotarget"},{"key":"2025120203430494600_ref6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3892\/ol.2024.14750","article-title":"Genetic evaluation of patients with multiple primary cancers","volume":"29","author":"Freire","year":"2024","journal-title":"Oncol Lett"},{"key":"2025120203430494600_ref7","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/his.15106","article-title":"Mesothelioma in the pleura, pericardium and peritoneum: recommendations from the international collaboration on cancer reporting (ICCR)","volume":"84","author":"Klebe","year":"2024","journal-title":"Histopathology"},{"key":"2025120203430494600_ref8","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat Genet"},{"key":"2025120203430494600_ref9","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/1479-5876-10-179","article-title":"BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs","volume":"10","author":"Carbone","year":"2012","journal-title":"J Transl Med"},{"key":"2025120203430494600_ref10","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3322\/caac.21572","article-title":"Mesothelioma: scientific clues for prevention, diagnosis, and therapy","volume":"69","author":"Carbone","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"2025120203430494600_ref11","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"Thorac Oncol"},{"key":"2025120203430494600_ref12","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2018.78.5204","article-title":"Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma","volume":"36","author":"Panou","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025120203430494600_ref13","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat Genet"},{"key":"2025120203430494600_ref14","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.jtho.2022.03.014","article-title":"Medical and surgical care of patients with mesothelioma and their relatives carrying germline BAP1 mutations","volume":"17","author":"Carbone","year":"2022","journal-title":"J Thorac Oncol"},{"key":"2025120203430494600_ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.03.008","article-title":"New pathogenic germline variants identified in mesothelioma","volume":"179","author":"Belcaid","year":"2023","journal-title":"Lung Cancer"},{"key":"2025120203430494600_ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.27351","article-title":"Germline variants incidentally detected via tumor-only genomic profiling of patients with mesothelioma","volume":"6","author":"Mitchell","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2025120203430494600_ref17","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s11912-023-01479-1","article-title":"Genomic landscape of pleural mesothelioma and therapeutic aftermaths","volume":"25","author":"Nash","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"2025120203430494600_ref18","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12967-018-1559-7","article-title":"Detecting germline BAP1 mutations in patients with peritoneal mesothelioma: benefits to patient and family members","volume":"16","author":"Kittaneh","year":"2018","journal-title":"J Transl Med"},{"key":"2025120203430494600_ref19","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/s41431-023-01448-z","article-title":"Clinical practice guidelines for the diagnosis and surveillance of BAP1 tumour predisposition syndrome","volume":"31","author":"Lalloo","year":"2023","journal-title":"Eur J Hum Genet"},{"key":"2025120203430494600_ref20","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1093\/jnci\/djy171","article-title":"Comprehensive study of the clinical phenotype of germline BAP1 variant-carrying families worldwide","volume":"110","author":"Walpole","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"2025120203430494600_ref21","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1200\/CCI.20.00124","article-title":"Microsimulation model for evaluating the cost-effectiveness of surveillance in BAP1 pathogenic variant carriers","volume":"5","author":"Walpole","year":"2021","journal-title":"JCO Clin Cancer Inform"},{"key":"2025120203430494600_ref22","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.annepidem.2017.04.001","article-title":"Epidemiology of mesothelioma of the pericardium and tunica vaginalis testis","volume":"27","author":"Mezei","year":"2017","journal-title":"Ann Epidemiol"},{"key":"2025120203430494600_ref23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/978-3-319-53560-9_3","volume-title":"Asbestos and Mesothelioma","author":"Moolgavkar","year":"2017"},{"key":"2025120203430494600_ref24","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1080\/10408440903044928","article-title":"Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005","volume":"39","author":"Price","year":"2009","journal-title":"Crit Rev Toxicol"},{"key":"2025120203430494600_ref25","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1136\/oem.2003.010165","article-title":"Changing trends in US mesothelioma incidence","volume":"61","author":"Weill","year":"2004","journal-title":"Occup Environ Med"},{"volume-title":"NPCR and SEER \u2013 U.S. Cancer Statistics Public Use Database","author":"CDC","key":"2025120203430494600_ref26"},{"volume-title":"National Program of Cancer Registries and Surveillance, Epidemiology and End Results Program SEER*Stat Database: NPCR and SEER Incidence\u2014U.S. Cancer Statistics Public Use Research Database, 2023 Submission (2001\u20132021). United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute","key":"2025120203430494600_ref27"},{"volume-title":"U.S. Cancer Statistics Public Use Database","author":"CDC","key":"2025120203430494600_ref28"},{"volume-title":"Surveillance Research Program, National Cancer Institute SEER*Stat Software","key":"2025120203430494600_ref29"},{"volume-title":"Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence\u2014SEER Research Data, 8 Registries, Nov 2023 Sub (1975\u20132021) \u2014Linked to County Attributes\u2014Time Dependent (1990\u20132022) Income\/Rurality, 1969\u20132022 Counties. National Cancer Institute, DCCPS, Surveillance Research Program, Bethesda, Maryland. Released April 2024, Based on the November 2023 Submission","key":"2025120203430494600_ref30"},{"key":"2025120203430494600_ref31","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1136\/oem.2009.052860","article-title":"Mesothelioma risk from chrysotile","volume":"67","author":"Hodgson","year":"2010","journal-title":"Occup Environ Med"},{"key":"2025120203430494600_ref32","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0003-4878(00)00045-4","article-title":"The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure","volume":"44","author":"Hodgson","year":"2000","journal-title":"Ann Occup Hyg"},{"key":"2025120203430494600_ref33","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1136\/oem.51.12.804","article-title":"Malignant mesothelioma: attributable risk of asbestos exposure","volume":"51","author":"Spirtas","year":"1994","journal-title":"Occup Environ Med"},{"key":"2025120203430494600_ref34","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/jnci\/djj106","article-title":"Prospective study of mesothelioma mortality in Turkish villages with exposure to fibrous zeolite","volume":"98","author":"Baris","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"2025120203430494600_ref35","first-page":"398","article-title":"Relation of environmental exposure to erionite fibres to risk of respiratory cancer","author":"Simonato","year":"1989","journal-title":"IARC Sci Publ"},{"key":"2025120203430494600_ref36","doi-asserted-by":"publisher","first-page":"111","DOI":"10.4415\/ANN_14_02_02","article-title":"Incidence of pleural mesothelioma in a community exposed to fibres with fluoro-edenitic composition in Biancavilla (Sicily, Italy)","volume":"50","author":"Bruno","year":"2014","journal-title":"Ann Ist Super Sanita"},{"key":"2025120203430494600_ref37","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1080\/00039890009604036","article-title":"Unusually high incidence of malignant pleural mesothelioma in a town of eastern Sicily: an epidemiological and environmental study","volume":"55","author":"Paoletti","year":"2000","journal-title":"Arch Environ Health"},{"key":"2025120203430494600_ref38","doi-asserted-by":"publisher","first-page":"753","DOI":"10.5858\/arpa.2017-0365-RA","article-title":"Malignant mesothelioma and its non-asbestos causes","volume":"142","author":"Attanoos","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"2025120203430494600_ref39","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1007\/s10552-009-9357-4","article-title":"Ionizing radiation: a risk factor for mesothelioma","volume":"20","author":"Goodman","year":"2009","journal-title":"Cancer Causes Control"},{"key":"2025120203430494600_ref40","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/cam4.4436","article-title":"Relationship between exposure to ionizing radiation and mesothelioma risk: a systematic review of the scientific literature and meta-analysis","volume":"11","author":"Visci","year":"2022","journal-title":"Cancer Med"},{"volume-title":"Risk Factors for Mesothelioma","author":"ACS","key":"2025120203430494600_ref41"},{"key":"2025120203430494600_ref42","doi-asserted-by":"crossref","DOI":"10.1016\/j.envres.2022.114582","article-title":"Multistage carcinogenesis: impact of age, genetic, and environmental factors on the incidence of malignant mesothelioma","volume":"230","author":"Moolgavkar","year":"2023","journal-title":"Environ Res"}],"container-title":["Journal of Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpubhealth\/article-pdf\/47\/4\/e540\/64218375\/fdaf110.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpubhealth\/article-pdf\/47\/4\/e540\/64218375\/fdaf110.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T08:43:10Z","timestamp":1764664990000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpubhealth\/article\/47\/4\/e540\/8248878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,7]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,9,7]]},"published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/pubmed\/fdaf110","relation":{},"ISSN":["1741-3842","1741-3850"],"issn-type":[{"type":"print","value":"1741-3842"},{"type":"electronic","value":"1741-3850"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,9,7]]}}}